Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study

Table 5

Efficacy and safety of rivaroxaban in patients with pulmonary embolism combined with or without tumor.

Duration	Efficacy		PE with tumor (18)	PE without tumor (68)		value
Efficacy	Disappeared	57	11 (61.11%)	46 (67.65%)	0.0917	0.7620
	Effective	16	2 (11.11%)	14 (20.59%)	0.6871	0.4072
	No effect	5	1 (5.56%)	4 (5.88%)	0.0026	0.9592
	Progressed	2	1 (5.56%)	1 (1.47%)	1.0212	0.3122
	Reappeared	2	0 (0%)	2 (2.94%)	0.5294	0.4669
	—	4	3 (16.67%)	1 (1.47%)
Bleeding	No bleeding	42	9 (50%)	33 (48.53%)	0.0063	0.9367
	Mild bleeding	38	7 (38.89%)	31 (45.59%)	0.1446	0.7038
	Serve bleeding	1	1 (5.56%)	0 (0%)	3.7778	0.0519
	Major bleeding	1	0 (0%)	1 (1.47%)	0.2647	0.6069
	—	4	1 (5.56%)	3 (4.41%)
	Death	3	3 (16.67%)	0 (0%)	11.333	<0.001